Dr. Missling has a relatively modest wage as industry standards go. He is taking options - and placing his bets alongside shareholders.
They didn't "promise" to start several trials... they expected to do so. CNS guidance was just released within the last month. Big Pharma has been abandoning CNS trials like rats leaving a sinking ship.
Anavex is tuned into the changes at the FDA and will benefit, IMO.